The XBI (biotech) index in the US is showing strong signs of life as investors adjust their thinking to sectors less vunerable to global and domestic events. Kazia's dual listing may well prove to be beneficial as it shakes off the minor effects of the recent ATM.
https://www.nasdaq.com/market-activity/funds-and-etfs/xbi